Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative – Group 3 Pulmonary Hypertension
Related Posts
Apaydin EA, Richard J, Miner SA, Waymouth M, Roberts D, Vockley J, Richardson AS. Evaluating selected gene therapies for cardiovascular diseases: an updated scoping review[...]
Girard AA, Jones PG, Fu Z, Sherrod CF 4th, Cantu Martinez O, Greene SJ, Bachmann JM, Fonarow GC, Butler J, Spertus JA, Arnold SV. Interrelationships[...]
Eibl G, Hines OJ, Rozengurt E. Prevention Before Therapy in Pancreatic Ductal Adenocarcinoma: The Clinical, Economic, and Human Case for Weighting Resources Upstream. Cancer Prev[...]